A comprehensive evaluation of the prognostic relevance of biomarkers such as the ALB concentration and NT-pro BNP level is pivotal for evaluating the overall risk of AF recurrence in patients with HFpEF. This evidence concerns the gene NPPB and atrial fibrillation.